SCHEMBL1406231

SCHEMBL1406231

COC(=O)CCC(C(C)=O)C(C)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.55
SLC1A1 P43005 1/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 3/20 0.40
CA12 O43570 2/20 0.40
CA14 Q9ULX7 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239453 0.89 TSHR (0.48) TSHRSLC1A1MGAMGAASI
SCHEMBL17190723 0.86 TSHR (0.44) TSHRSLC1A1MGAMGAASI
SCHEMBL28576166 0.84 L3MBTL1 (0.45) TSHRSLC1A1MGAMGAASI
SCHEMBL17190718 0.82 TSHR (0.41) TSHRSLC1A1MGAMGAASI
SCHEMBL17995485 0.81 TSHR (0.40) TSHRSLC1A1MGAMGAASI
SCHEMBL8686256 0.81 TSHR (0.55) TSHRSLC1A1MGAMGAASI
SCHEMBL12951358 0.79 TSHR (0.52) TSHRSLC1A1MGAMGAASI
SCHEMBL11062326 0.79 TSHR (0.52) TSHRSLC1A1MGAMGAASI
SCHEMBL23734825 0.77 SLC1A1 (0.55) TSHRSLC1A1MGAMGAASI
SCHEMBL1406208 0.77 L3MBTL1 (0.50) TSHRMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
US-4895872-A TREATING HYPERACTIVE IMMUNE SYSTEMS; AUTOIMMUNE AND GRAFT/HOST DISEASES CETUS CORPORATION (US) 1990-01-23 US claimed
WO-1990000049-A2 IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE CETUS CORPORATION (US) 1990-01-11 WO claimed
US-6410805-B1 None US disclosed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US disclosed
CN-118084638-A Continuous production method and device of 1, 3-cyclohexanedione 宁波天研精开技术有限公司 2024-05-28 CN disclosed
CN-113336629-B Preparation process of 1,3 cyclohexanedione 上海埃农生物科技有限公司 2023-09-01 CN disclosed
CN-113292525-B Preparation method of delta caprolactone 上海埃农生物科技有限公司 2022-07-05 CN disclosed
CN-113292525-A Preparation method of delta caprolactone 上海埃农生物科技有限公司 2021-08-24 CN disclosed
US-10123978-B2 Patch for treating dermatophytosis MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-11-13 US disclosed
EP-2881114-B1 ANTI-TRICHOPHYTIC ADHESIVE PATCH MEIJI SEIKA PHARMA CO LTD (JP) 2018-09-05 EP disclosed
US-5453514-A Diabetes YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1995-09-26 US disclosed
US-5252603-A Immunosuppressive analogues and derivatives of succinylacetone CETUS CORPORATION (US) 1993-10-12 US disclosed
US-5216005-A Treating autoimmune diseases, organ tissue transplants CETUS CORPORATION (US) 1993-06-01 US disclosed
US-5173482-A A dioxoalkyl phosponate or a proline-modified polyoxyethylene glycol derivative; autoimmune diseases; organ transplants; immunoassay CETUS CORPORATION (US) 1992-12-22 US disclosed
US-5100885-A Hypoxic tumor cells are rendered more susceptible to destruction by radiation JOHNSON MATTHEY, INC. (US) 1992-03-31 US disclosed
WO-1991004734-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING 4,6-TIOXOHEPTANOIC ACID OR ITS DERIVATIVES CETUS CORPORATION (US) 1991-04-18 WO disclosed
EP-0411935-A2 Copper radio sensitizers JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1991-02-06 EP disclosed
US-4895872-A TREATING HYPERACTIVE IMMUNE SYSTEMS; AUTOIMMUNE AND GRAFT/HOST DISEASES CETUS CORPORATION (US) 1990-01-23 US disclosed
WO-1990000049-A2 IMMUNOSUPPRESSIVE ANALOGUES AND DERIVATIVES OF SUCCINYLACETONE CETUS CORPORATION (US) 1990-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10123978-B2 Patch for treating dermatophytosis DPM1, KRT18, LCP1 TSHR 4300/4885SLC1A1 446/4885MGAM 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.